345 completed, 100 terminated, 67 recruiting, 55 unknown. 635 Phase 3, 132 Phase 2.
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) GV1001 Placebo, GV1001 1.12mg - Moderate to Severe Alzheimer's Disease | Phase 3 | Not yet recruiting | Samsung Pharmaceutical Co., Ltd. | 750 | 2027-07-01 | 2026-06-10 |
| A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia Xanomeline/trospium - Schizophrenia; Psychosis, Cognitive Impairment | Phase 3 | Not yet recruiting | European Group for Research In Schizophrenia | 171 | 2027-01-01 | 2026-05-13 |
| International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial Guideline-directed medical therapy (GDMT), Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI). - Coronary Artery Disease, Cognitive Impairment | Phase 3 | Suspended | NYU Langone Health | 1200 | 2026-12-01 | 2026-06-05 |
| Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study Tricaprilin, Placebo - Alzheimer Disease | Phase 3 | Not yet recruiting | Cerecin | 535 | 2026-12-01 | 2026-07-01 |
| A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Hoffmann-La Roche | 1600 | 2026-11-30 | 2026-10-13 |
| Impact on Delirium of the Use of DEXmedetomidine as First-line Sedation in PEDIAtric Intensive Care Dexmedetomidine, Midazolam - Delirium in the Intensive Care Unit | Phase 3 | Not yet recruiting | University Hospital, Tours | 266 | 2026-11-15 | 2026-09-28 |
| Lactium Premedication to Prevent Emergence Agitation Lactium - Lactium, Premedication | Phase 3 | Not yet recruiting | Tanta University | 40 | 2026-11-10 | 2026-10-27 |
| Effect of Nebulized Lignocaine on Emergence Agitation After Sevoflurane Anesthesia in Pediatric Patients Undergoing Tonsillectomy Lidocaine, 0.9% Normal Saline - Emergence Agitation, Emergence Delirium | Phase 3 | Not yet recruiting | Assiut University | 60 | 2026-11-01 | 2026-10-13 |
| To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) Acoramidis (AG10) - Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial | Phase 3 | Not yet recruiting | Eidos Therapeutics, a BridgeBio company | 250 | 2026-11-01 | 2026-08-11 |
| A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects T3D-959, Placebo Comparator - Alzheimer's Disease | Phase 2 / Phase 3 | Not yet recruiting | T3D Therapeutics, Inc. | 376 | 2026-10-26 | 2025-05-09 |
| KetAmine and Recovery After Mechanical VentilAtion ( KARMA ) Intervention Group, Placebo - Critical Illness | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 640 | 2026-10-19 | 2026-05-15 |
| Intrathecal Dexmedetomidine and Postoperative Delirium in Elderly Hip Fracture Surgery Dexmedetomidine, Hyperbaric Bupivacaine with Normal Saline - Postoperative Delirium, Hip Fractures | Phase 2 / Phase 3 | Not yet recruiting | Assiut University | 130 | 2026-10-01 | 2026-09-09 |
| An Open-label Long-term Safety Study of Buntanetap in Participants With AD buntanetap/posiphen - Alzheimer's Dementia (AD) | Phase 2 / Phase 3 | Not yet recruiting | Annovis Bio Inc. | 400 | 2026-09-21 | 2026-08-19 |
| Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD. [18F]-APN-1607 - Alzheimer's Disease | Phase 3 | Recruiting | JYAMS PET Research & Development Limited | 12 | 2026-08-15 | 2026-08-17 |
| Alzheimer's Disease THErapy With NEuroaid II MLC 901, Placebo - Alzheimer's Disease Dementia | Phase 3 | Not yet recruiting | Moleac Pte Ltd. | 350 | 2026-08-01 | 2026-06-12 |
| A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease Donanemab, RG6289, Donanemab placebo - Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease | Phase 2 / Phase 3 | Recruiting | Banner Health | 240 | 2026-07-08 | 2026-09-02 |
| Ketofol Versus Ketodex for POD Prophylaxis in Elderly Cancer Surgery Group ketofol, Group ketodex, Group Control - Postoperative Delirium (POD) | Phase 3 | Recruiting | Cairo University | 180 | 2026-07-01 | 2026-06-04 |
| Oral Versus Intravenous Magnesium on Emergence Delirium Magnesium glycinate, Magnesium sulfate injection, Oral juice and intravenous saline - Magnesium, Emergence Delirium | Phase 2 / Phase 3 | Recruiting | Tanta University | 360 | 2026-07-01 | 2026-07-06 |
| Pridopidine Phase 3 Study in Huntington's Disease Pridopidine, Placebo - Huntington Disease | Phase 3 | Recruiting | Prilenia | 400 | 2026-07-01 | 2026-10-28 |
| A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy NIO752, Placebo - Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 300 | 2026-06-03 | 2026-10-15 |
Showing 20 of 635. Sign in to see all of them.
Alzheimer Disease (346) · Dementia (138) · Cognitive Dysfunction (131) · Delirium (63) · Emergence Delirium (41) · Psychomotor Agitation (35) · Huntington Disease (29) · Memory Disorders (25) · Cognition Disorders (24) · Dementia, Vascular (24) · Mental Disorders (20) · Nervous System Diseases (19) · Brain Diseases (18) · Neurodegenerative Diseases (16) · Schizophrenia (15)
Mental Disorders (615) · Nervous System Diseases (559) · Central Nervous System Diseases (450) · Brain Diseases (443) · Neurodegenerative Diseases (374) · Tauopathies (339) · Dementia (298) · Pathological Conditions, Signs and Symptoms (227) · Signs and Symptoms (201) · Neurologic Manifestations (197) · Neurobehavioral Manifestations (178) · Cognition Disorders (165) · Confusion (98) · Pathologic Processes (86)
Donepezil (30) · Dexmedetomidine (25) · Galantamine (24) · Memantine (20) · Saline Solution (15) · Haloperidol (13) · Rivastigmine (12) · Sodium Chloride (11) · gantenerumab (10) · latrepirdine (10) · Melatonin (8) · donanemab (8) · florbetapir (8) · flutemetamol (8) · solanezumab (8)
Eli Lilly and Company (22) · Hoffmann-La Roche (15) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (15) · Pfizer (15) · Otsuka Pharmaceutical Development & Commercialization, Inc. (14) · Assistance Publique - Hôpitaux de Paris (12) · National Institute on Aging (NIA) (10) · Novartis Pharmaceuticals (10) · Washington University School of Medicine (10) · Avid Radiopharmaceuticals (9) · Eisai Inc. (8) · Bristol-Myers Squibb (7) · GE Healthcare (7) · H. Lundbeck A/S (7) · FORUM Pharmaceuticals Inc (6)
United States (329) · Canada (157) · France (116) · United Kingdom (113) · Germany (111) · Spain (109) · Australia (104) · Italy (89) · Poland (68) · Netherlands (67) · South Korea (64) · Japan (63) · China (55) · Argentina (50) · Belgium (50)
Randall J Bateman, MD (5) · Ilise Lombardo, MD (3) · James Kupiec, MD (3)
PMID 39498781, PMID 40603145, PMID 39800465, PMID 26120369, PMID 26402769, PMID 33189083, PMID 40681915, PMID 41533472, PMID 41537338, PMID 41961243, PMID 29318278, PMID 30474567, PMID 31193334, PMID 36946603, PMID 39108660, PMID 39556389, PMID 41591746, PMID 42552749, PMID 42841310, PMID 20921879, PMID 22749065, PMID 24450890, PMID 24450891, PMID 25125457, PMID 26208959, PMID 26297092, PMID 27176461, PMID 27334799, PMID 27494299, PMID 27767991, PMID 27807285, PMID 28265459, PMID 28269765, PMID 29615123, PMID 29854934, PMID 29854935, PMID 30412493, PMID 30558645, PMID 31353964, PMID 31390660, PMID 31708380, PMID 31764959, PMID 31831056, PMID 32107748, PMID 32524297, PMID 33049114, PMID 33070419, PMID 33587110, PMID 34807243, PMID 34923848
2015 (10), 2016 (10), 2025 (9), 2017 (6), 2023 (5), U01AG010483 (5), U01AG059798 (5), 2018 (4), R01AG046179 (4), U01AG042791 (4), 2009 (3), R01AG053267 (3), R56AG053267 (3), 1RC2AG036535 (2), 2019 (2)